Panel Presentation 1B: The Emerging Role of GLP-1 Receptor Agonists in Addiction Care: Early Experience and Future Directions

At Caron Treatment Centers, we are actively integrating GLP-1 receptor agonists (GLP-1RAs) into residential addiction treatment as part of a broader effort to future-proof how treatment organizations address craving, metabolic health, and relapse vulnerability. To date, more than 450 patients in our system have been treated with these agents, giving us one of the largest real-world clinical experiences with GLP-1s in addiction care anywhere in the country.

This session is not a sales pitch for a new medication, nor a claim that GLP-1s are a “silver bullet.” Instead, it is a leadership-level examination of what happens when powerful new craving-modulating technologies begin to change the clinical and economic landscape of treatment. As pharmacology, neuroscience, and metabolic medicine converge, treatment centers will increasingly be forced to reevaluate not only clinical protocols, but also their product mix, service lines, staffing models, and care delivery architecture.

We will review where GLP-1s fit in the evolving neurobiology of addiction and craving, how they relate conceptually to existing tools (e.g., buprenorphine, naltrexone, acamprosate), and what they realistically can—and cannot—be expected to do. More importantly, we will explore what it means for a treatment organization when medications meaningfully suppress craving, change patient trajectories, and potentially alter length of stay, acuity curves, and post-discharge needs.

The core of the session will focus on real-world implementation: cultural resistance, operational friction, insurance barriers, staff concerns, patient expectations, and the clinical boundary-setting required to responsibly deploy these medications in residential settings. We will share what has worked, and what we have had to redesign in real time.

Finally, we will zoom out to the strategic question: how treatment organizations can future-proof themselves in an era of rapidly evolving craving-suppressing therapies. The goal is to leave executives and clinical leaders not with a protocol, but with a durable framework for evaluating innovation, reorganizing services, and evolving their care models while staying anchored to mission, ethics, and clinical integrity.